Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-22-ALSRP-CBDA: DoD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award

Closed Closed July 28, 2022 Opportunity W81XWH-22-ALSRP-CBDA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.

• Total funding$8.0 million
• Expected awards10
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The intent of the FY22 ALSRP Clinical Biomarker Development Award (CBDA) is to maximize clinical ALS resources and biorepositories to better define subtypes, assess prognosis, or predict therapeutic response and to improve value of clinical trials. Applications should focus on the development and improvement of clinical biomarkers to enrich clinical trials in ALS. Biomarkers may be predictive/cohort-selective, prognostic, and/or pharmacodynamic. Biomarker development or data analysis can be relevant to a specific therapeutic or class of therapeutics, or to a specific type of ALS (such as a particular genetic mutation) and does not have to broadly apply to all patients. Analysis of results and/or biosamples collected under these projects should be made broadly available through deposition in existing publicly available curated repositories and data platforms when possible. Clinical trials are not allowed for this award mechanism. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Investigators interested in intervention clinical trials should consider applying under the FY22 ALSRP Pilot Clinical Trial Award (Funding Opportunity Number: W81XWH-22-ALSRP-PCTA). For information about other FY22 ALSRP award mechanisms, see https://cdmrp.army.mil/funding/alsrp. Use of existing well-characterized and highly curated clinical resources is encouraged. Examples of human-based ALS resources include ongoing or completed clinical trial datasets, biorepositories of clinical specimens, large transcriptome/proteome/metabolomic datasets, and databases of clinical data and/or metadata. The applicant must demonstrate availability of, and accessibility to, the necessary resources to accomplish the proposed aims. Resources should be available at the time of application submission, however, collection of new specimens and/or data from participants in an existing cohort is allowed. Applications are encouraged to include diversity in their sample populations. A list of suitable resources can be found on the ALSRP web page (https://cdmrp.army.mil/ alsrp/resources/ALSRPresources). Other resources may be used, provided they have an adequate description of repository parameters and mechanisms for broad access.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.